FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W73766050> ?p ?o ?g. }

• W73766050 endingPage "262" @default.
• W73766050 startingPage "259" @default.
• W73766050 abstract "Free AccessCPAPMild Obstructive Sleep Apnea Syndrome Should be Treated Lee K. Brown, MD. Lee K. Brown, MD. Address correspondence to: Lee K. Brown, MD, Professor of Medicine and Pediatrics, Executive Director, Program in Sleep Medicine, University of New Mexico Health Sciences Center, 1101 Medical Arts Avenue NE, Building #2, Albuquerque, NM 87102(505) 272-6110(505) 272-6112 E-mail Address: [email protected] Sleep Disorders Center, University of New Mexico, Albuquerque, NM Search for more papers by this author Published Online:April 15, 2007https://doi.org/10.5664/jcsm.26793Cited by:11SectionsPDF ShareShare onFacebookTwitterLinkedInRedditEmail ToolsAdd to favoritesDownload CitationsTrack Citations AboutINTRODUCTIONWhat little I remember from high school concerning debating technique consists of the Jesuit adage, “define your terms.” Consequently, I will begin by reviewing the possible criteria by which obstructive sleep apnea (OSA) could be considered “mild” in degree. The various attributes attached to OSA include the presence of symptoms (most frequently, hypersomnia), as well as various metrics obtained from the overnight polysomnogram. The latter include degree of oxyhemoglobin desaturation, which might encompass saturation nadir, total sleep time (TST) below a certain saturation, or mean saturation; respiratory-associated arousal index; or apnea-hypopnea index (AHI). Although the definition of “mild” OSA could be the subject of its own debate, the American Academy of Sleep Medicine has, in fact, taken a position on this issue.1 Two criteria are used: sleepiness, which must be either absent or mild in degree (only occurring in sedentary situations), and AHI, which must fall between 5 and 15 events per hour of sleep. Unfortunately, mild OSA in clinical research has almost universally been defined only in terms of AHI, usually that in the range of 5–15. This definition must then suffice for purposes of this debate.Having defined mild OSA, I will frame my argument for treating this degree of sleep apnea by outlining the evidence that: (1) Mild OSA can cause symptoms; (2) Mild OSA can lead to adverse sequelae; (3) Mild OSA can be treated; and (4) Treating mild OSA can lead to improved outcomes. Fortunately, there are now several population studies that can aid us in this endeavor. With respect to symptoms, data from the Sleep Heart Health Study2 have demonstrated a significant relationship between AHI and sleepiness as measured by the Epworth Sleepiness Scale (ESS).3 When compared to subjects with AHI <5, mean ESS values rose steadily as OSA severity category increased from “minimal” to “severe”; with sleepiness defined as ESS ≥11, 28% of subjects with AHI between 5 and 15 were sleepy compared to 21% of those with AHI <5.2 Data from the Wisconsin Sleep Cohort Study are even more intriguing: subjects with snoring but AHI <5, presumably a degree of sleep disordered breathing considerably less than “mild,” had significantly more complaints of excessive daytime sleepiness, awakening feeling unrefreshed, and uncontrollable sleepiness interfering with life (all ≥2 days/week) compared with nonsnoring controls.4 The Sleep Heart Health Study has also demonstrated a significant worsening of quality of life in subjects with mild OSA.5 Compared with controls, the odds ratio for subjects with AHI between 5 and 15 reporting a poor quality of life on the Medical Outcomes Study 36-item Short-Form health survey (SF-36)6 Vitality Scale was 1.20 (95% confidence interval or CI, 1.02–1.43).The same two population studies (Sleep Heart Health and Wisconsin Sleep Cohort) have provided important information linking mild OSA with adverse cardiovascular and metabolic outcomes. Cross sectional data from the former study demonstrated a linear relationship between blood pressure and AHI starting with the most minor degree of severity: prevalence of hypertension was 43% for AHI <1.5, 53% for AHI between 1.5 and 4.9, and 59% for AHI between 5 and 14.9; this relationship held even after adjustment for body mass index (BMI).7 Prospective data from the Wisconsin Sleep Cohort have proven an even stronger relationship in terms of 4-year incidence of developing hypertension: compared to subjects with AHI=0, odds ratios (and 95% confidence intervals) for incident hypertension were 1.42 (1.13–1.78) for AHI between 0.1 and 4.9 and 2.03 (1.29 – 3.17) for AHI between 5 and 14.9.8 The same investigators had previously demonstrated a cross-sectional prevalence relationship,9 as have several other groups analyzing other populations.10,11Similar results have been obtained in cross-sectional investigations of cardiovascular disease prevalence. The Sleep Heart Health Study demonstrated a “modest and significant linear” relationship between relative odds of cardiovascular disease (coronary heart disease, heart failure, and stroke) and quartile of AHI, starting with the mildest quartile (AHI = 1.4–4.4).12 Few studies are available thus far examining incident risk of cardiovascular disease in OSA, and none include a well-characterized group with mild OSA. For instance, Peker et al reported prospective data from a group of 182 middle-aged men from the Gothenburg Sleep Clinic Cohort who entered the study without cardiovascular disease.13 Patients with incompletely-treated OSA had more incident cardiovascular events than controls after 7 years of follow-up, but OSA severity was not accurately measured by today's standards: oxygen desaturation index in the OSA group was 16.5 ± 15.3 (mean ± standard deviation or SD), suggesting a predominantly mild-moderate level of disease. Also, Marin and colleagues published prospective observational data on 403 patients with untreated mild to moderate OSA (AHI between 5 and 30) compared to 264 controls, and demonstrated a tendency toward increased fatal and non-fatal cardiovascular events in the patient group after about 9 years of follow-up.14 It is hoped that future publications from the Wisconsin Sleep Cohort, the Sleep Heart Health Study, or other ongoing prospective studies will provide more information on this issue.Three reports illustrate a possible association between insulin resistance/glucose intolerance and mild OSA. One examined a subset (n= 2,656) of the Sleep Heart Health Study in which all enrollees had fasting blood glucose determinations, followed by a 75 gm glucose challenge and 2-hour glucose determination in 1,930 of the subjects.15 Adjusted odds ratio for elevated fasting glucose (as a marker of glucose intolerance) was 1.27 (95% CI, 0.98–1.64) for subjects with AHI between 5 and 15 compared with controls (AHI <5), and there was a significant overall trend with increasing severity of AHI. The odds ratio for an abnormal 2-hour glucose was 0.88 (95% CI, 0.88–1.35) in the mild OSA group, but again with a significant overall trend. The second study, by Ip and coworkers, examined fasting insulin levels and homeostasis model assessment method (HOMA-IR) as indices of insulin resistance in 270 patients.16 All were referred for evaluation of possible OSA and none had a history of physician-diagnosed diabetes. Using multiple linear regression, they demonstrated that AHI was an independent determinant of insulin resistance in both obese and lean subjects. The last study examined 4-year incident diabetes mellitus in 978 subjects from the Wisconsin Sleep Cohort.17 The odds ratio for developing diabetes for subjects with AHI between 5 and 15, compared to those with AHI <5, was 1.83 (95% CI, 1.07–3.11) when adjusted for sex and age; when adjusted for sex, age, and waist girth, statistical significance was lost (odds ratio, 1.25; 95% CI, 0.75–2.07). However, there is a known relationship between visceral fat (and thus waist girth) and OSA;18 furthermore, visceral fat is known to regress after OSA is treated.19 Consequently, adjusting for waist girth in this study may actually have obscured a bona fide relationship to incident diabetes.Supporting evidence that is not epidemiological in nature is also available. Three small studies of carotid artery sonographic markers of early atherosclerosis have demonstrated abnormalities in mild OSA. All defined mild severity as an AHI between 5 and 19; observed AHI was 12.9 ± 3.8 (mean ± SD) in one study,20 11.0 ± 0.9 (mean ± standard error of the mean, or SEM) in the second,21 and 16.2 ± 1.7 (mean ± SD) in the third,22 thereby largely adhering to my working definition of mild OSA. The latter study also demonstrated differences in a separate index of early atherosclerosis, carotid-femoral pulse wave velocity.22 Most recently, Duchna and coworkers studied 10 normal controls and 10 patients with mild OSA (AHI between 5 and 15) with respect to maximum endothelium-dependent vasodilation to bradykinin.23 This index of early vascular endothelium dysfunction was abnormal in mild OSA compared to controls, and significantly improved after CPAP treatment in 7 of the mild OSA patients. Finally, one large-scale investigation derived from the Sleep Heart Health Study examined 1,037 elderly subjects by means of sonographic measurement of baseline brachial artery diameter and percentage of flow-mediated dilation.24 A dose-response relationship was present between both measures of endothelial dysfunction and AHI when corrected for demographic variables, starting with the mildest degree of OSA. However, these relationships were not significant when adjustment was added for BMI and serum cholesterol.The issue of whether mild OSA is treatable can be dealt with in short order. “Life-style” treatments such as weight loss and avoidance of alcohol and respiratory depressant drugs near to bedtime have an adjunctive role, but are not considered primary therapeutic modalities.25 Sleep position training in those individuals shown to have significant OSA only when supine is usually easily accomplished (unless musculoskeletal disease makes non-supine sleep too uncomfortable) and effective.25–27 Mandibular advancement devices have proven to be viable options in treating mild OSA, with perhaps no single issue in sleep medicine having been subjected to as many systematic reviews and meta-analyses as this therapeutic modality. These include 1995 and 2005 reviews and practice parameters by the American Academy of Sleep Medicine,28–31 a Cochrane Collaboration review,32 and systematic reviews by Hoekema et al,33 Ng et al,34 and Hoffstein.35 All analyses indicate that mandibular advancement devices are appropriate for the treatment of mild OSA as long as efficacy is verified in any individual patient, and that self-reported compliance with treatment is high (frequently higher than with positive airway pressure treatment). Conventional surgical treatment of OSA incorporates uvulopalatopharyngoplasty for oropharyngeal obstruction with or without base-of-tongue procedure(s) meant to address hypopharyngeal obstruction. Practice parameters and a review by the American Academy of Sleep Medicine some 10 years ago did not support the routine use of these procedures for OSA treatment,36,37 and a recent Cochrane Collaboration review sustained that recommendation.38 A thorough discussion of surgery for mild OSA is beyond the scope of this paper, save to note that it can be efficacious in some patients and thereby obviates the need to assess compliance. Finally, positive airway pressure (PAP) remains the reference standard for OSA treatment in that significant amelioration of obstructive respiratory events is virtually guaranteed as long as the device is actually worn.39 Patients with mild OSA, particularly those who are asymptomatic, can be significantly less inclined to use their PAP device compared with individuals with more severe, or more symptomatic, OSA.40 However, multiple clinical trials in patients with relatively mild degrees of OSA have still shown that substantial compliance is likely (Table 1).41–45 Given the availability of these multiple effective treatment modalities, it seems clear that mild OSA can be treated in most patients.Table 1 Compliance with positive airway pressure treatment in mild to moderate OSA.Reference numberNAHIFollow-up TimeCompliance, hours/nightCompliance, Other Metric412921.6 ± 7.5a3 weeks4.9(0–8.4)b62% of nights with >4 hours428821.3 ± 1.3c3 months3.6 ± 0.3c43% with ≥4 hours use for 70% of nights432812.9 ± 6.3a8 weeks3.53 ± 2.13a48% with >4 hours use/night444831 ± 26a2 months4.9 ± 2.4an/a456620 ± 6a6 months4.8 ± 2.2a64% with >4 hours use/nightastandard deviationbrangecstandard error of the mean.The final issue is that of whether treatment of mild OSA measurably improves outcome. Thus far, virtually all reports investigating the efficacy of treating milder degrees of OSA have focused on continuous PAP (CPAP) as the treatment modality, and hypersomnia as the measured outcome. There are 7 studies that have used ESS score as an outcome metric: 2 compared CPAP to conservative treatment45,47 (neither was a crossover trial), and 5 were placebo controlled41–43,46,48 (4-placebo medication, 1-sham CPAP). All but one of the latter studies used a crossover design. Subject enrollment ranged from 16 to 125, with a median study population of 34 and a total number of subjects across all studies of 409. Two studies, for a total of 50 patients, required an AHI of 5–15 for enrollment;46,48 4 studies enrolled subjects with AHI of 5–30;41–43,47 one study limited AHI to 10–30.45 Marshall and colleagues have published a meta-analysis of pooled data from these 7 reports and found a significant improvement in ESS score (a reduction of 1.2 points; 95% CI = 0.5–1.9, p = 0.001) comparing placebo/conservative treatment to active treatment.49 Three of these studies also performed maintenance of wakefulness tests,41,42,48 and the meta-analysis of pooled data from these reports revealed a significant increase in mean sleep latency on active treatment of 2.1 minutes (95% CI, 0.5–3.7; p = 0.011).49 It is also instructive to examine more closely the 2 trials that concentrated on the mildest degree of OSA (AHI between 5 and 15), those by Engleman and colleagues.46,48 The first of these, a pilot study of 16 patients, demonstrated no significant improvement in sleepiness, but improvement in a measure of quality of life in the subjects with best CPAP compliance.46 The second study examined a new group of 34 subjects in a placebo-controlled crossover design.48 An average CPAP use of 2.8 hours/night resulted in significant improvements in ESS score (11 ± 4 points on placebo vs. 8 ± 4 points on CPAP, p = 0.008); 2 tests of cognitive performance (Digit Symbol Substitution subtest of the Wechsler Intelligence Scale-Revised, and the Paced Auditory Serial Addition Test); and multiple tests of psychological well-being, health, and functional status (Hospital Anxiety and Depression Scale-depression, SF-36 Health Transition, Role-Physical, Bodily Pain, Social Function, and Vitality scales).In conclusion, the accumulating literature on mild OSA (as defined by an AHI between 5 and 15) provides clear evidence that disease of this modest severity can be symptomatic, can lead to adverse consequences, can be treated, and that such treatment will lead to improvement in some outcomes. The fact that these improved outcomes relate particularly to patient quality of life leads me to conclude that treatment is indeed beneficial even in mild OSA and should be pursued.Disclosure StatementThis is not an industry supported study. Dr. Brown has received research support from ResMed Corporation.REFERENCES1 American Academy of Sleep Medicine Task ForceSleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical researchSleep19992266789, 10450601 CrossrefGoogle Scholar2 Gottlieb DJ, Whitney CW, Bonekat WH, et al.Relation of sleepiness to respiratory disturbance index. The Sleep Heart Health StudyAm J Respir Crit Care Med19991595027, 9927364 CrossrefGoogle Scholar3 Johns MWA new method for measuring daytime sleepiness: The Epworth sleepiness scaleSleep1991145405, 1798888 CrossrefGoogle Scholar4 Young T, Palta M, Dempsey J, et al.The occurrence of sleep-disordered breathing among middle-aged adultsN Engl J Med199332812305, 8464434 CrossrefGoogle Scholar5 Baldwin CM, Griffith KA, Nieto J, et al.The association of sleep-disordered breathing and sleep symptoms with quality of life in the Sleep Heart Health StudySleep20012496105, 11204058 CrossrefGoogle Scholar6 Stewart AL, Hays RD, Ware JEThe MOS short-form general health survey: reliability and validity in a patient populationMed Care19882672435, 3393032 CrossrefGoogle Scholar7 Nieto FJ, Young TB, Lind BK, et al.Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based studyJAMA2000283182936, 10770144 CrossrefGoogle Scholar8 Peppard PE, Young T, Palta M, et al.Prospective study of the association between sleep-disordered breathing and hypertensionN Engl J Med2000342137884, 10805822 CrossrefGoogle Scholar9 Young T, Peppard P, Palta M, et al.Population-based study of sleep-disordered breathing as a risk factor for hypertensionArch Intern Med1997157174652, 9250236 CrossrefGoogle Scholar10 Lavie P, Herer P, Hoffstein VObstructive sleep apnoea syndrome as a risk factor for hypertension: population studyBMJ200032047982, 10678860 CrossrefGoogle Scholar11 Bixler EO, Vgontzas AN, Lin HM, et al.Association of hypertension and sleep-disordered breathingArch Intern Med2000160228995, 10927725 CrossrefGoogle Scholar12 Shahar E, Whitney CW, Redline S, et al.Sleep-disordered breathing and cardiovascular disease. Cross-sectional results of the Sleep Heart Health StudyAm J Respir Crit Care Med20011631925, 11208620 CrossrefGoogle Scholar13 Peker Y, Hedner J, Norum J, et al.Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea. A 7-year follow-upAm J Respir Crit Care Med200216615965, 12119227 CrossrefGoogle Scholar14 Marin JM, Carrizo SJ, Vicente E, et al.Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational studyLancet2005365104653, 15781100 CrossrefGoogle Scholar15 Punjabi NM, Shahar E, Redline S, et al.Sleep-disordered breathing, glucose intolerance, and insulin resistance. The Sleep Heart Health StudyAm J Epidemiol200416052130, 15353412 CrossrefGoogle Scholar16 Ip MSM, Lam B, Ng MMT, et al.Obstructive sleep apnea is independently associated with insulin resistanceAm J Respir Crit Care Med20021656706, 11874812 CrossrefGoogle Scholar17 Reichmuth KJ, Austin D, Skatrud JB, et al.Association of sleep apnea and type II diabetes. A population-based studyAm J Respir Crit Care Med200517215905, 16192452 CrossrefGoogle Scholar18 Vgontzas AN, Papanicolaou DA, Bixler EO, et al.Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemiaJ Clin Endocrinol Metab20008511518, 10720054 CrossrefGoogle Scholar19 Chin K, Shimizu K, Nakamura T, et al.Changes in intra-abdominal visceral fat and serum leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapyCirculation199910070612, 10449691 CrossrefGoogle Scholar20 Altun R, Özdemir H, Mahmutyazicioğlu K, et al.Evaluation of carotid artery wall thickness with high-resolution sonography in obstructive sleep apnea syndromeJ Clin Ultrasound200533806, 15674835 CrossrefGoogle Scholar21 Minoguchi K, Yokoe T, Tazaki T, et al.Increased carotid intima-media thickness and serum inflammatory markers in obstructive sleep apneaAm J Respir Crit Care Med200517262530, 16120716 CrossrefGoogle Scholar22 Drager LF, Bortolotto LA, Lorenzi MC, et al.Early signs of atherosclerosis in obstructive sleep apneaAm J Respir Crit Care Med20051726138, 15901608 CrossrefGoogle Scholar23 Duchna H-W, Stoohs R, Guilleminault C, et al.Vascular endothelial dysfunction in patients with mild obstructive sleep apnea syndromeWien Med Wochenschr2006156596604, 17160377 CrossrefGoogle Scholar24 Nieto FJ, Herrington DM, Redline S, et al.Sleep apnea and markers of vascular endothelial function in a large community sample of older adultsAm J Respir Crit Care Med200416935460, 14551166 CrossrefGoogle Scholar25 Morgenthaler TI, Kapen S, Lee-Chiong T, et al.Practice parameters for the medical therapy of obstructive sleep apneaSleep200629103135, 16944671 CrossrefGoogle Scholar26 Cartwright R, Ristanovic R, Diaz F, et al.A comparative study of treatments for positional sleep apneaSleep19911454652, 1798889 CrossrefGoogle Scholar27 Jokic R, Klimaszewski A, Crossley M, et al.Positional treatment vs continuous positive airway pressure in patients with positional obstructive sleep apnea syndromeChest199911577181, 10084491 CrossrefGoogle Scholar28 Schmidt-Nowara W, Lowe A, Wiegand L, et al.Oral appliances for the treatment of snoring and obstructive sleep apnea: a reviewSleep19951850110, 7481421 CrossrefGoogle Scholar29 American Sleep Disorders AssociationPractice parameters for the treatment of snoring and obstructive sleep apnea with oral appliancesSleep1995185113, 7481422 CrossrefGoogle Scholar30 Ferguson KA, Cartwright R, Rogers R, et al.Oral appliances for snoring and obstructive sleep apneaSleep20062924462, 16494093 CrossrefGoogle Scholar31 Kushida CA, Morgenthaler TI, Littner MR, et al.Practice parameters for the treatment of snoring and obstructive sleep apnea with oral appliances: an update for 2005Sleep2006292403, 16494092 CrossrefGoogle Scholar32 Lim J, Lasserson TJ, Fleetham J, et al.Oral appliances for obstructive sleep apnoeaCochrane Database of Systematic Reviews2006CD004435144 Google Scholar33 Hoekema A, Stegenga B, de Bont LGMEfficacy and co-morbidity of oral appliances in the treatment of obstructive sleep apnea-hypopnea: a systematic reviewCrit Rev Oral Biol Med20041513755, 15187032 CrossrefGoogle Scholar34 Ng A, Gotsopoulos H, Darendeliler AM, et al.Oral appliance therapy for obstructive sleep apneaTreat Respir Med2005440922, 16336026 CrossrefGoogle Scholar35 Hoffstein VReview of oral appliances for treatment of sleep-disordered breathingSleep Breath200711122, 17136406 CrossrefGoogle Scholar36 Standards of Practice Committee of the American Sleep Disorders AssociationPractice parameters for the treatment of obstructive sleep apnea in adults: the efficacy of surgical modifications of the upper airwaySleep1996191525, 8855038 CrossrefGoogle Scholar37 Sher AE, Schechtman KB, Piccirillo JFThe efficacy of surgical modifications of the upper airway in adults with obstructive sleep apnea syndromeSleep199619156177, 8855039 CrossrefGoogle Scholar38 Sundaram S, Bridgman SA, Lim J, et al.Surgery for obstructive sleep apnoeaCochrane Database of Systematic Reviews2005CD001004145 Google Scholar39 Gay P, Weaver T, Loube D, et al.Evaluation of positive airway pressure treatment for sleep related breathing disorders in adults. A review by the positive airway pressure task force of the standards of practice committee of the American Academy of Sleep MedicineSleep200629381401, 16553025 CrossrefGoogle Scholar40 Krieger J, Kurtz D, Petiau C, et al.Long-term compliance with CPAP therapy in obstructive sleep apnea patients and in snorersSleep199619SupplS13643, 9122571 CrossrefGoogle Scholar41 Marshall NS, Neill AM, Campbell AJ, et al.Randomised controlled crossover trial of humidified continuous positive airway pressure in mild obstructive sleep apnoeaThorax20056042732, 15860720 CrossrefGoogle Scholar42 Barnes M, McEvoy RD, Banks S, et al.Efficacy of positive airway pressure and oral appliance in mild to moderate obstructive sleep apneaAm J Respir Crit Care Med200417065664, 15201136 CrossrefGoogle Scholar43 Barnes M, Houston D, Worsnop CJ, et al.A randomized controlled trial of continuous positive airway pressure in mild obstructive sleep apneaAm J Respir Crit Care Med200216577380, 11897643 CrossrefGoogle Scholar44 Engleman HM, McDonald JP, Graham D, et al.Randomized crossover trial of two treatments for sleep apnea/hypopnea syndrome. Continuous positive airway pressure and mandibular repositioning splintAm J Respir Crit Care Med20021668559, 12231497 CrossrefGoogle Scholar45 Monasterio C, Vidal S, Duran J, et al.Effectiveness of continuous positive airway pressure in mild sleep apnea-hypopnea syndromeAm J Respir Crit Care Med200116493943, 11587974 CrossrefGoogle Scholar46 Engleman H, Martin S, Deary I, et al.Effect of CPAP therapy on daytime function in patients with mild sleep apnoea/hypopnoea syndromeThorax1997521149, 9059469 CrossrefGoogle Scholar47 Redline S, Adams N, Strauss ME, et al.Improvement of mild sleep disordered breathing with CPAP compared with conservative therapyAm J Respir Crit Care Med199815785865, 9517603 CrossrefGoogle Scholar48 Engleman H, Kingshott R, Wraith P, et al.Randomized placebo controlled crossover trial of continuous positive airway pressure for mild sleep apnea/hypopnea syndromeAm J Respir Crit Care Med19991594617, 9927358 CrossrefGoogle Scholar49 Marshall NS, Barnes M, Travier N, et al.Continuous positive airway pressure reduces daytime sleepiness in mild to moderate obstructive sleep apnea: a meta-analysisThorax2006614304, 16467072 CrossrefGoogle Scholar Previous article Next article FiguresReferencesRelatedDetailsCited by Cerebral white matter diffusion properties and free‐water with obstructive sleep apnea severity in older adultsBaril A, Gagnon K, Descoteaux M, Bedetti C, Chami S, Sanchez E, Montplaisir J, De Beaumont L, Gilbert D, Poirier J, Pelleieux S, Osorio R, Carrier J and Gosselin N Human Brain Mapping, 10.1002/hbm.24971, Role of autologous platelet-rich fibrin in relocation pharyngoplasty for obstructive sleep apnoeaElkahwagi M, Elokda M, Elghannam D and Elsobki A International Journal of Oral and Maxillofacial Surgery, 10.1016/j.ijom.2019.05.008, Vol. 49, No. 2, (200-206), Online publication date: 1-Feb-2020. Adherence to CPAPBakker J, Weaver T, Parthasarathy S and Aloia M Chest, 10.1016/j.chest.2019.01.012, Vol. 155, No. 6, (1272-1287), Online publication date: 1-Jun-2019. Sleep hygiene-related conditions in patients with mild to moderate obstructive sleep apneaJung S, Kim H, Min J, Hwang K and Kim S Auris Nasus Larynx, 10.1016/j.anl.2018.06.003, Vol. 46, No. 1, (95-100), Online publication date: 1-Feb-2019. A Conditional Inference Tree Model for Predicting Sleep-Related Breathing Disorders in Patients With Chiari Malformation Type 1: Description and External ValidationFerré Á, Poca M, de la Calzada M, Moncho D, Urbizu A, Romero O, Sampol G and Sahuquillo J Journal of Clinical Sleep Medicine, Vol. 15, No. 01, (89-99), Online publication date: 15-Jan-2019. Metabolic Profile in Patients with Mild Obstructive Sleep ApneaSilva L, Guimarães T, Luz G, Coelho G, Badke L, Almeida I, Millani-Carneiro A, Tufik S, Bittencourt L and Togeiro S Metabolic Syndrome and Related Disorders, 10.1089/met.2017.0075, Vol. 16, No. 1, (6-12), Online publication date: 1-Feb-2018. Using the STOPBANG questionnaire and other pre-test probability tools to predict OSA in younger, thinner patients referred to a sleep medicine clinicMcMahon M, Sheikh K, Andrada T and Holley A Sleep and Breathing, 10.1007/s11325-017-1498-1, Vol. 21, No. 4, (869-876), Online publication date: 1-Dec-2017. Treatment of primary aldosteronism is associated with a reduction in the severity of obstructive sleep apnoeaWolley M, Pimenta E, Calhoun D, Gordon R, Cowley D and Stowasser M Journal of Human Hypertension, 10.1038/jhh.2017.28, Vol. 31, No. 9, (561-567), Online publication date: 1-Sep-2017. Comparison of American Academy of Sleep Medicine (AASM) versus Center for Medicare and Medicaid Services (CMS) polysomnography (PSG) scoring rules on AHI and eligibility for continuous positive airway pressure (CPAP) treatmentKorotinsky A, Assefa S, Diaz-Abad M, Wickwire E and Scharf S Sleep and Breathing, 10.1007/s11325-016-1327-y, Vol. 20, No. 4, (1169-1174), Online publication date: 1-Dec-2016. An Official American Thoracic Society Research Statement: Impact of Mild Obstructive Sleep Apnea in AdultsChowdhuri S, Quan S, Almeida F, Ayappa I, Batool-Anwar S, Budhiraja R, Cruse P, Drager L, Griss B, Marshall N, Patel S, Patil S, Knight S, Rowley J and Slyman A American Journal of Respiratory and Critical Care Medicine, 10.1164/rccm.201602-0361ST, Vol. 193, No. 9, (e37-e54), Online publication date: 1-May-2016. Berry R Obstructive Sleep Apnea Treatment Overview and Medical Treatments Fundamentals of Sleep Medicine, 10.1016/B978-1-4377-0326-9.00018-X, (299-312), . Volume 03 • Issue 03 • April 15, 2007ISSN (print): 1550-9389ISSN (online): 1550-9397Frequency: Monthly Metrics History Published onlineApril 15, 2007 Information© 2007 American Academy of Sleep MedicinePDF download" @default.
• W73766050 created "2016-06-24" @default.
• W73766050 creator A5012400074 @default.
• W73766050 date "2007-04-15" @default.
• W73766050 modified "2023-09-26" @default.
• W73766050 title "Mild Obstructive Sleep Apnea Syndrome Should be Treated" @default.
• W73766050 cites W108214990 @default.
• W73766050 cites W147768144 @default.
• W73766050 cites W1487772832 @default.
• W73766050 cites W1788205751 @default.
• W73766050 cites W185591369 @default.
• W73766050 cites W197066864 @default.
• W73766050 cites W1977228997 @default.
• W73766050 cites W1977426271 @default.
• W73766050 cites W1995141700 @default.
• W73766050 cites W1997188928 @default.
• W73766050 cites W2007920108 @default.
• W73766050 cites W2017127718 @default.
• W73766050 cites W2034556696 @default.
• W73766050 cites W2035557978 @default.
• W73766050 cites W2037464054 @default.
• W73766050 cites W2046131459 @default.
• W73766050 cites W2047132452 @default.
• W73766050 cites W2051344677 @default.
• W73766050 cites W205664854 @default.
• W73766050 cites W2079982868 @default.
• W73766050 cites W2084292135 @default.
• W73766050 cites W2093930698 @default.
• W73766050 cites W2098864100 @default.
• W73766050 cites W2099193524 @default.
• W73766050 cites W2099593277 @default.
• W73766050 cites W2099915725 @default.
• W73766050 cites W2100204228 @default.
• W73766050 cites W2105727933 @default.
• W73766050 cites W2118855061 @default.
• W73766050 cites W2119213758 @default.
• W73766050 cites W2126987431 @default.
• W73766050 cites W2127030366 @default.
• W73766050 cites W2132840057 @default.
• W73766050 cites W2137130170 @default.
• W73766050 cites W2138197709 @default.
• W73766050 cites W2139704316 @default.
• W73766050 cites W2141493724 @default.
• W73766050 cites W2146465989 @default.
• W73766050 cites W2156000474 @default.
• W73766050 cites W2157191239 @default.
• W73766050 cites W2158367419 @default.
• W73766050 cites W2286275570 @default.
• W73766050 cites W2333343699 @default.
• W73766050 cites W2335449614 @default.
• W73766050 cites W2415975763 @default.
• W73766050 cites W2546647298 @default.
• W73766050 cites W2557901763 @default.
• W73766050 cites W2785563066 @default.
• W73766050 cites W41627501 @default.
• W73766050 cites W4300562130 @default.
• W73766050 doi "https://doi.org/10.5664/jcsm.26793" @default.
• W73766050 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2564769" @default.
• W73766050 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17561591" @default.
• W73766050 hasPublicationYear "2007" @default.
• W73766050 type Work @default.
• W73766050 sameAs 73766050 @default.
• W73766050 citedByCount "21" @default.
• W73766050 countsByYear W737660502012 @default.
• W73766050 countsByYear W737660502014 @default.
• W73766050 countsByYear W737660502016 @default.
• W73766050 countsByYear W737660502017 @default.
• W73766050 countsByYear W737660502018 @default.
• W73766050 countsByYear W737660502019 @default.
• W73766050 countsByYear W737660502020 @default.
• W73766050 countsByYear W737660502021 @default.
• W73766050 countsByYear W737660502022 @default.
• W73766050 countsByYear W737660502023 @default.
• W73766050 crossrefType "journal-article" @default.
• W73766050 hasAuthorship W73766050A5012400074 @default.
• W73766050 hasBestOaLocation W737660501 @default.
• W73766050 hasConcept C111919701 @default.
• W73766050 hasConcept C126322002 @default.
• W73766050 hasConcept C164705383 @default.
• W73766050 hasConcept C177713679 @default.
• W73766050 hasConcept C1862650 @default.
• W73766050 hasConcept C187212893 @default.
• W73766050 hasConcept C2775841894 @default.
• W73766050 hasConcept C2776006263 @default.
• W73766050 hasConcept C2777935920 @default.
• W73766050 hasConcept C2778205975 @default.
• W73766050 hasConcept C2781326671 @default.
• W73766050 hasConcept C41008148 @default.
• W73766050 hasConcept C71924100 @default.
• W73766050 hasConcept C99508421 @default.
• W73766050 hasConceptScore W73766050C111919701 @default.
• W73766050 hasConceptScore W73766050C126322002 @default.
• W73766050 hasConceptScore W73766050C164705383 @default.
• W73766050 hasConceptScore W73766050C177713679 @default.
• W73766050 hasConceptScore W73766050C1862650 @default.
• W73766050 hasConceptScore W73766050C187212893 @default.
• W73766050 hasConceptScore W73766050C2775841894 @default.
• W73766050 hasConceptScore W73766050C2776006263 @default.

• next